GL GLOBE LIFE INC. Insider Trading

Director Cheryl Alston sells 8,258 shares for $1,480,134.16 at Globe Life; retains 16,621 shares post-transaction

Cheryl Alston, Globe Life Director, executed 4 separate sales totaling 8,258 shares for $1,480,134.16 on 2026-06-25, with transaction prices ranging from $177.56 to $180.13. The sales reduced her holdings by 33.2% from 24,879 to 16,621 shares, a material reduction in her ownership stake. The blended average sale price of $179.24 sits near the 52-week high of $181.15 and well above the current price of $178.42, suggesting the director executed trades during a period when the stock was trading near its recent peak. The stock is trading -1.5% from its 52-week high but has appreciated +15.6% over 30 days and +32.1% over 90 days, reflecting recent strong performance at the time of sale.

Co-Chairman & CEO Frank M Svoboda sells 20,000 shares (27.0% of non-derivative holding) for $3.3M across 4 transactions at $164.20–$166.93

Frank M Svoboda, who was Co-Chairman & CEO at the time of filing, executed 4 separate sales totaling 20,000 shares (20.0K shares) for $3,315,645.76 ($3.3M) at prices ranging from $164.20 to $166.93, reducing his non-derivative holdings from 74,020 shares to 54,020 shares (-27.0% vs pre-transaction holdings). The transactions occurred on 2026-06-11 and 2026-06-12, with a blended average price of $165.78, near the current price of $169.06 and within 0.3% of the 52-week high of $169.50. Svoboda retains 10,000 shares through employee stock options (Table II derivative holdings), so his overall position remains substantial. His cross-ticker track record shows 20 prior sells with an average 90-day return of +3.1% and a 53.85% well-timed rate; however, his same-ticker history at GL shows 5 prior sales with only 2 measurable 30-day outcomes (both marginally positive), and no completed 90-day windows yet, making predictive assessment of this sale's timing impossible. The stock has risen 9.0% in 30 days and 21.0% in 90 days; whether this sale represents a tactical reduction or scheduled vest-and-sell activity cannot be determined from the filing alone.

EVP & CFO Thomas Peter Kalmbach sold 7,936 shares of GL at $156.59 on 2026-05-22, reducing holdings to 50,495 shares; 5 prior GL sells all posted negative 90d returns.

On 2026-05-22, Thomas Peter Kalmbach (EVP & CFO) sold 7,936 shares at $156.59, reducing his holdings by -13.6% to 50,495 shares. The stock is trading near its 52-week high of $157.92 at current price $156.70, up 8.7% over 90 days. Notably, across Kalmbach's 5 prior sales at GL, all posted negative 90-day returns (ranging from -1.4% to -2.8%), with a 90-day well-timed rate of 100% at this ticker. His cross-ticker track record on 8 prior sells shows an average 90-day return of -3.2% with a 100% well-timed rate. The company has solid fundamentals: $1.6B in latest-quarter revenue, $270.5M net income, and a P/E of 10.34. The question for investors is whether this sale—given the consistent negative post-sale price movements in Kalmbach's prior GL transactions—represents another instance of the pattern, or a break from it in a market that has recently rallied.

Frank M Svoboda sold 20,000 shares at blended avg $156.68 for $3.1M; post-sale holdings 54,020 shares (-27.0% reduction).

Frank M Svoboda, who was Co-Chairman & CEO of Globe Life Inc., executed 2 separate sales totaling 20,000 shares for $3,133,587.54 at prices ranging from $156.65 to $157.05 on 2026-05-22, reducing his stake from 74,020 to 54,020 shares. The sales occurred at prices very close to the 52-week high of $157.92 (current price $156.70 is -0.8% from that peak), and the stock has risen +2.7% in the prior 30 days and +8.7% in the prior 90 days. His prior 5 trades at this ticker all resulted in subsequent positive returns at the 90-day mark (ranging from +1.3% to +1.8%), with 0 of 5 classified as well-timed on that metric, suggesting his recent sell pattern at this ticker has not preceded material declines. The company trades at a P/E of 10.34 with stable fundamentals (revenue $1,559,619,000.00, net income $270,526,000.00, annual revenue growth +3.7%), indicating no obvious fundamental distress signal.

CFO Kalmbach sold 11,903 shares of GL at $156.61 for $1.9M; 5 of 5 prior GL sales were well-timed with negative 90d returns.

Thomas Peter Kalmbach, EVP & CFO, sold 11,903 shares at $156.61 on 2026-05-19, reducing his holdings by 19.7% from 60,334 to 48,431 shares. His prior trading pattern at GL is notable: all 5 previous sales were well-timed at the 90-day mark, each followed by stock declines ranging from -1.4% to -2.8% over 90 days. The current sale price of $156.61 is -2.4% from the 52-week high of $157.92, placing it near but slightly below recent peaks. GL trades at a P/E of 10.16 with $1.6B in latest quarterly revenue and a $12.0B market cap, fundamentals that provide context for evaluating the signal. Investors should monitor whether this sale follows the established pattern of his prior GL trades or represents a departure from his timing accuracy at this ticker.

Globe Life CFO Kalmbach acquires 35,000 shares net while selling 27,427; mixed-timing insider with strong 90-day track record but conflicting short-term signals.

Kalmbach, the company's Chief Financial Officer, executed a complex two-day set of transactions on May 8–11 that netted an acquisition of 35,000 shares, making this his first open-market purchase in the three-year filing window. The trade is notable because it occurs in a company with solid fundamentals—profitable with modest revenue growth—and the stock trades very near its 52-week high. Kalmbach's prior trading record at this ticker is mixed: his four earlier sales have all proven well-timed as the stock declined after each exit, yet his one prior purchase showed poor timing with shares falling in the following month before recovering over a longer period. The current transaction's unusual structure—simultaneous buying and selling across two days—suggests active rebalancing rather than conviction-based accumulation, and the fact that he sold nearly as many shares as he acquired complicates the bullish signal that a pure acquisition might otherwise send.

CEO Frank Svoboda executes large sale near 52-week highs while maintaining buy activity, signaling selective profit-taking.

Frank Svoboda, Globe Life's Co-Chairman and CEO, executed a complex transaction pattern on consecutive days that reveals selective profit-taking rather than wholesale portfolio reduction. Despite a net outflow of over $2.3 million in sales, Svoboda simultaneously made material purchases, suggesting he is pruning positions that have appreciated while maintaining conviction in the company. The stock is currently trading near its 52-week high and has appreciated meaningfully over the past quarter — a classic setup for insider profit-taking without abandonment. Historically, Svoboda's prior sales in this stock preceded periods where the stock either fell or remained flat, making his timing track record reasonably reliable. The underlying company remains fundamentally sound and profitable, indicating Svoboda is not panicking but rather making deliberate rebalancing decisions at an attractive price level.

Globe Life Co-Chairman & CEO Darden buys $2.2M shares while simultaneously selling $3.4M stake, net reduction.

Darden James Matthew, the Co-Chairman and CEO of Globe Life, executed a mixed trade on a single day: purchasing approximately 22,000 shares while selling roughly 22,000 shares across two transactions, netting a reduction in his overall position. The purchase price on the buy side was substantially lower than the sale prices, suggesting some tactical repositioning rather than conviction buying—he's trimming an existing stake at elevated levels while redeploying a portion into a lower entry point. Globe Life is a profitable company with steady revenue and a conservative valuation, which provides a reasonable backstop for his existing holdings. However, Darden's pattern of primarily selling (12 prior sells versus only 2 buys in his track record) and five recent GL sells dating back months signal a consistent trimming bias that reflects portfolio management rather than emerging insider confidence in a turnaround or material positive catalyst.

Co-Chairman and CEO Frank Svoboda exercises and immediately sells equal-sized blocks, netting $530k gain while stock trades near 52-week highs.

Frank Svoboda, Globe Life's Co-Chairman and CEO, exercised 10,000 shares and sold 10,000 shares in the same transaction date, creating a net-zero change in his position. This is a classic equity exercise-and-sell pattern — compensation vesting followed by immediate liquidation — rather than a reflection of insider conviction about the stock's direction. The sales occurred as the stock trades near its 52-week highs, a common window for executives to realize value from vested equity without signaling concerns about future performance. Svoboda's prior Form 4 activity over the past three years shows 23 prior open-market sales against only 2 purchases, establishing a strong seller-oriented pattern. At the ticker level, his five prior sells at Globe Life show mixed timing results — three were well-timed exits (the stock fell after those sales) while two were poorly timed (the stock rose afterward) — indicating inconsistent success reading this specific company's near-term direction. Against a backdrop of solid company fundamentals—profitable operations with modest revenue growth and reasonable valuation—this transaction reads as routine equity management rather than a directional bet.

GL Co-Chair Darden sells 4,663 shares for $717.5K at $153.88 amid strong 11.8% 30-day run; his sells timed poorly historically (avg 90d +0.1% cross-ticker, 62.5% well-timed rate)

Darden James Matthew, GL's Co-Chairman & CEO, sold 4,663 shares at $153.88 on 2026-04-28, reducing his holdings by 7.4% to 58,451 shares. This transaction occurs after a notable 11.8% 30-day price gain and at the 52-week high of $153.97, near the top of the recent run. Examining his cross-ticker sell history, his 11 prior open-market sales averaged a 90-day return of -0.1% with a 62.5% well-timed rate, indicating his sales have historically not been reliable timing signals. At GL specifically, his prior 2 measurable sales were split (one up 5.0% and 2.7% at 30 days, one down 6.3% and 6.7% at 30 days), providing minimal historical pattern. The stock trades at a P/E of 9.67 with $1.5B quarterly revenue and solid 3.7% annual growth, but the absence of material news context and his modest historical timing success suggest the market should treat this sale as routine rebalancing by leadership rather than a bearish signal.